Small Caps

Pre-revenue small caps: why normal valuation rules often fail

Pre-revenue small caps are valued on evidence, funding and milestones, not normal profit ratios. Here is how to test the story before risking money.

By Cameron Oliver · May 27, 2026

Pre-revenue small caps can be exciting because the upside story is easy to imagine. They can also be dangerous because the usual valuation shortcuts often stop working. When there is little or no revenue, you are not valuing a stable business. You are weighing evidence, funding risk and the chance that the story survives long enough to become real.

Reviewed by James Whitfield, Senior Editor. Last reviewed 28 May 2026.

In this article

The Short Version

Key Takeaways

Pre-revenue small caps often cannot be judged with normal price-to-earnings or dividend measures.
The useful questions are about cash runway, dilution, technical progress, customer proof and management credibility.
A low market value does not automatically mean a company is cheap. It may simply mean the risk is high.
The biggest danger is paying for a future that needs several successful fundraises before ordinary shareholders benefit.
A clear checklist helps you separate evidence from promotion.

Why Normal Valuation Rules Break Down

Many investing tools assume a company already has profits, cash flow or at least meaningful revenue. A pre-revenue small cap may have none of those. It might be a biotech company waiting for trial data, a mining explorer waiting for drilling results, a clean-tech developer building a first commercial plant, or a software company still proving demand.

That makes ratios such as price to earnings almost useless. There are no earnings to compare. Dividend yield is also irrelevant because the company is more likely to need cash than return it. Even price to sales can be weak if early sales are tiny, lumpy or not yet representative of the final business.

So the question changes. Instead of asking, “Is this cheap against current profits?”, you ask, “What evidence exists, what has to happen next, and how much more money will be needed before this becomes a real business?”

Start With Cash Runway

Cash runway is the first test because a pre-revenue company lives or dies by funding. Look at the latest cash balance, then compare it with the operating cash outflow. If the company spent £6 million in cash last year and has £3 million left, the runway may be measured in months, not years.

Runway is not only an accounting detail. It tells you who has bargaining power. A company with enough cash to reach its next milestone can negotiate from a stronger position. A company that needs money urgently may have to issue shares at a poor price, accept tough financing terms, or slow the project.

For shareholders, the key question is simple: does the company have enough cash to reach the next value-changing event without another placing?

Dilution Is Part Of The Valuation

Pre-revenue companies often raise money by issuing new shares. That can be necessary and sensible. It can also dilute existing holders heavily. If a company doubles its share count to fund the next stage, your slice of the business gets smaller unless the new money creates enough value to compensate.

This is why a low share price can be misleading. A share may look cheap at 2p, but if the share count keeps rising, the market value may still be high relative to the evidence. Always look at market capitalisation, not just the share price.

Then look at the history. Has the company repeatedly raised money below previous prices? Does management explain funding needs early, or does each placing arrive as a surprise? Are warrants attached to fundraises? Those details can change the real cost for ordinary shareholders.

Milestones Matter More Than Promises

A pre-revenue company needs milestones because revenue is not yet doing the judging. In biotech, that might mean trial results, regulatory decisions or partnership agreements. In mining, it might mean drilling, resource estimates, permits or project financing. In technology, it might mean paid pilots, retention data or repeat customer contracts.

Good milestones are specific and externally testable. “We are seeing strong interest” is weak. “We have signed three paid pilots with named customers” is stronger. “We expect first production in the second half” is useful only if you can see the steps needed to get there.

Write down the next two milestones and the rough date expected. If you cannot do that, the investment case may be too vague.

Management Credibility Is Not A Bonus

In a pre-revenue company, management credibility carries more weight than usual because investors are being asked to trust a plan before the numbers prove it. Look for people who have built, financed or sold similar projects before. Also look for honest communication when milestones slip.

Small-cap investors should be wary of permanent optimism. Every early-stage company faces setbacks. The useful board is not the one that never admits problems. It is the one that explains delays, protects cash and updates investors before the pressure becomes obvious.

Director ownership can help, but it is not enough on its own. A meaningful stake is useful only if the board is disciplined about funding, pay and communication.

A Worked Example

Imagine a pre-revenue battery materials company with a market value of £20 million. It has £4 million of cash and spends about £500,000 a month. That gives it roughly eight months of runway before costs change.

The company says a pilot plant could prove the process next year. That sounds promising, but the valuation question is not just whether the technology might work. You also need to ask how much cash is needed to reach pilot results, how much more is needed after that, and whether customers have signed anything binding.

If the company needs another £10 million before it has reliable proof, existing shareholders may face dilution before the biggest question is answered. The upside may still be real, but the current valuation must be judged against that funding path.

What This Means For You

Pre-revenue small caps are not automatically bad. Some early-stage companies do become valuable businesses. The problem is that many look cheap because the share price is low, while the actual risk sits in the funding gap.

Your checklist should cover five things: cash runway, dilution history, next milestone, evidence quality and management credibility. If any one of those is weak, the valuation needs a much bigger margin of safety.

It also helps to decide in advance what would make you change your mind. A missed milestone, an emergency placing or vague customer language may be more important than a short-term share price move.

In Plain English

A pre-revenue small cap is valued on what might happen, not what is already proven. That makes the opportunity look larger, but it also makes the risk harder to see. Do not ask only how big the prize could be. Ask how many fundraises, delays and technical hurdles stand between today’s shareholders and that prize.